Status:
COMPLETED
Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month
Lead Sponsor:
Nordic Myeloma Study Group
Collaborating Sponsors:
Nordic Cancer Union
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Multiple myeloma is a malignant hematological disease dominated by monoclonal plasma cells in the bone marrow. Major symptoms are related to the bones due to an increased bone resorption and a decreas...
Detailed Description
Patients with newly diagnosed treatment demanding multiple myeloma are after informed consent and approved inclusion criteria randomised by telephone call to Copenhagen Trial Unit (CTU) and informatio...
Eligibility Criteria
Inclusion
- New diagnosed multiple myeloma with treatment demanding disease
Exclusion
- Life-expectancy less than 3 months, another active malignant disease, treatment with bisphosphonates for more than 3 months within the last 6 months, patients with creatinine above 400 µmol/l 4 weeks after starting chemotherapy, patients who cannot cooperate for monthly infusions, patients who do not give their informed consent
Key Trial Info
Start Date :
January 1 2000
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT00376883
Start Date
January 1 2000
End Date
October 1 2006
Last Update
January 4 2007
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Haematology B, Aalborg Hospital, University of Aarhus
Aalborg, Denmark, 9000
2
Hæmatologisk afd., Århus Universitetshospital
Aarhus, Denmark, DK-8000
3
Department of Haematology, Herlev University Hospital
Herlev, Denmark, 2730
4
Department of Hematology L, Rigshospitalet
København Ø, Denmark, DK-2100